CVT 2454
Latest Information Update: 16 Jul 2002
At a glance
- Originator CV Therapeutics
- Class
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis
Most Recent Events
- 17 Apr 2000 New profile
- 17 Apr 2000 Preclinical development for Coronary artery restenosis in USA (Unknown route)